New Long-Acting shot for schizophrenia enters early human testing

NCT ID NCT06674694

Recruiting now Disease control Sponsor: Sichuan Kelun Pharmaceutical Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This early-stage study is testing a single injection of a long-acting form of the drug brexpiprazole in healthy volunteers and people with schizophrenia. The main goal is to check if the injection is safe and tolerable, and how the body processes the drug. The trial involves 56 participants and will monitor side effects, vital signs, and lab tests for up to 90 days after the injection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brexpiprazole long-acting injection
What this could lead to: If successful, this could lead to a longer-acting treatment option for schizophrenia, potentially reducing the need for daily pills.
What could go wrong: This is an early Phase 1 trial with only 56 participants, focused on safety and dosing. It is too small and early to know if the injection will effectively control schizophrenia symptoms or have significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA DISORDERS

Contacts and locations

Locations

Beijing Anding Hospital Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.